|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
446.80 DKK |
+1.30% | +2.69% | -28.42% | |
Published on 05/07/2025 at 13:46
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Sector Update: Health Care |
01:46pm |
MT |
|
European shares slip as investors assess earnings, await Fed rate decision |
12:43pm |
RE |
|
European shares slip as investors assess earnings, await Fed rate decision |
12:43pm |
RE |
|
Novo Nordisk Tops Quarterly Views, Tempers Full-Year Outlook |
12:43pm |
MT |
|
US judge sides with FDA’s removal of Lilly’s weight loss drug from shortage list |
12:31pm |
RE |
|
Top Midday Stories: Treasury Secretary Bessent to Meet with Chinese Officials; AMD Shares Rise After Q1 Beat |
11:27am |
MT |
|
NOVO NORDISK : Compounders bite 2025 outlook; still an attractive proposition |
11:24am |
 |
|
Novo Nordisk to to Exclude US Operations from Global Initiative for Gender Representation |
11:18am |
MT |
|
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading |
11:07am |
MT |
|
Global markets live: Tesla, Amazon, Novo Nordisk, BMW, Boeing… |
10:49am |
 |
|
-Charles River agrees with Elliott to add new directors, review business |
10:12am |
RE |
|
Novo Nordisk latest drugmaker to drop gender goals in US |
09:59am |
RE |
|
Novo Nordisk Drops Gender Representation Goals in US |
09:56am |
MT |
|
Novo Nordisk hopes to see US Wegovy sales recover soon |
09:31am |
RE |
|
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday |
09:19am |
MT |
|
NOVO NORDISK : Jefferies still a seller |
09:16am |
CF |
|
Novo Nordisk hopes to see US Wegovy sales recover soon |
09:04am |
RE |
|
Sector Update: Health Care |
09:01am |
MT |
|
Novo Nordisk executive says expects FDA to enforce ban on copies of obesity drugs |
08:27am |
RE |
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as US, China Schedule Trade Talks |
08:19am |
MT |
|
Novo Nordisk latest drugmaker to drop gender goals in US |
08:03am |
RE |
|
Stocks Rise Pre-Bell Amid Optimism Over US-China Trade Talks; Fed Rate Decision Looms |
07:52am |
MT |
|
NOVO NORDISK : JP Morgan maintains a Buy rating |
07:38am |
ZD |
|
Cencora raises annual profit forecast on strong demand for specialty drugs |
07:18am |
RE |
|
Novo Nordisk A/S, Q1 2025 Earnings Call, May 07, 2025 |
07:00am |
NOVO B: Dynamic Chart
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
– diabetes and obesity treatment products (93.6%);
– rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).
More about the company
Buy
Last Close Price
441.05DKK
Average target price
699.59DKK
Spread / Average Target
+58.62%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
